Two friends and I discussed the article, and then one proposed something unbelievable: "We should do Whole30 together." After considering what Philipps' had to say about it, I decided to give it a try. Then Health editor in chief Lori Leibovich asked me to document my Whole30 experience with daily video diaries on Health Instagram stories, and I knew there was no turning back. I was about to do my first diet ever.
Thank you CFA coaches for always scaling the WOD for my medical needs, but still making the WOD fun and challenging. I may not be able to lift heavy or ever be a part of the CF games, but I do feel like a part of CFA family and with that I could never go back to a gym. It’s been a privilege meeting and working out with great people. I feel honored to be selected CFA Athlete of the Month. CROSSFIT PROUD!!!
In July 2016, a New York Times article on use of Instagram by dieters noted that participants in the Whole30 program had shared over one million Instagram posts using the #Whole30 hashtag, and noted that those sharing the tag were "one of seemingly endless like-minded communities," comparing it with the over 3.5 million posts under the #WeightWatchers hashtag.
During this program there is no calorie counting, no measuring, and no weighing yourself for the entire 30 days. I know that can be hard — especially if you’re feeling totally bloated (which can happen in the beginning) or particularly svelte in the later weeks. Just don’t do it. Even though a lot of people’s weight begins to normalize during the 30 days, the program focuses a lot on the “non-scale victories,” as in how you’re feeling. Is your sleep better? How’s your skin? Do you feel like doing cartwheels with that extra energy? Cool.
The WHO trial (so named because the international team of principal investigators contained World Health Organization members) tested the potential of clofibrate, a “pre-statin” cholesterol-lowering agent, to reduce heart attack morbidity and mortality. The investigators ultimately concluded that clofibrate "cannot be recommended as a lipid-lowering drug for community-wide primary prevention of ischaemic heart disease.” Nevertheless, clofibrate remained in use until 2002, when it was pulled for increasing cancer rates. In their review of studies such as the WHO trial, Uffe Ravnskov and David Diamond observe, “Despite the largely disappointing findings from 50 years of cholesterol lower[ing] trials, the indictment and conviction of cholesterol as the causal agent in CVD [cardiovascular disease] has stood the test of time. … [Yet] the grand effort to reduce cholesterol as a strategy to improve health has failed.”